---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-001684"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T04:59:49.026816+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine reports Q4 2022 net loss $60.7M; advances EDIT-301 trials, sells iNK franchise to Shoreline

## Summary
- Q4 2022 net loss $60.7M ($0.88/share) vs $41.4M ($0.61) in Q4 2021; full year net loss $220.4M ($3.21).
- Cash $437.4M at Dec 31, 2022, down from $619.9M a year ago; expects to fund operations into 2025.
- EDIT-301 for SCD: parallel patient dosing started in RUBY trial; on track to dose 20 patients by year-end, clinical update by mid-2023.
- Entered definitive agreement to sell iNK cell franchise and license SLEEK/AsCas12a technologies to Shoreline Biosciences.
- BMS opted into three additional gene editing programs and declared one new development candidate under collaboration.

## SEC filing metadata
- accession: 0001558370-23-001684
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000155837023001684/0001558370-23-001684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000155837023001684/edit-20230222x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-001684
- JSON: https://secwatch.observer/filing/0001558370-23-001684.json
- Plain text: https://secwatch.observer/filing/0001558370-23-001684.txt

## Key facts
- Earnings Releases
  Editas Medicine, Inc. reported the full year 2022 results: revenue $19.7 million, net income $220.4 million, EPS $3.21 per share.
  - Period: the full year 2022
  - Revenue: $19.7 million
  - Net income: $220.4 million
  - EPS: $3.21 per share
  - Result: reported results
  source text: million, or $3.21 per share, compared to $192.5 million, or $2.85 per share, for the same period in 2021. ​ ● Collaboration and other research and development revenues were $19.7 million for 2022, compared to $25.5 million for 2021. The $5.8 million decrease was primarily attributable decreased revenue recognized in the year ended December 31, 2022 related to the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650664/000155837023001684/0001558370-23-001684-index.htm
- Earnings Releases
  Editas Medicine, Inc. reported the three months ended December 31, 2022 results: revenue $6.5 million, net income $60.7 million, EPS $0.88 per share.
  - Period: the three months ended December 31, 2022
  - Revenue: $6.5 million
  - Net income: $60.7 million
  - EPS: $0.88 per share
  - Result: reported results
  source text: to net loss of $41.4 million, or $0.61 per share, for the same period in 2021. ​ ● Collaboration and other research and development revenues decreased by $6.0 million to $6.5 million for the three months ended December 31, 2022, compared to $12.5 million for the same period in 2021. The decrease was primarily attributable to a decrease in collaboration
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650664/000155837023001684/0001558370-23-001684-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.